Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RELY:
- Remitly Global price target raised to $27 from $20 at Goldman Sachs
- Remitly Global price target raised to $26 from $22 at Citizens
- Analyst Reaffirms Buy on Remitly, Maintaining $23 Price Target Amid Strong Profitability Progress and Attractive Valuation
- Remitly Global reports Q1 EPS 23c, consensus 29c
- Remitly Global sees FY26 revenue $1.96B-$1.975B, consensus $1.95B